Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of EGM

3 Jul 2014 11:36

RNS Number : 3708L
ViaLogy PLC
03 July 2014
 



3 July 2014

ViaLogy PLC

("Company")

 

Result of General Meeting

 

The Company announces that, at the General Meeting of the Company held earlier today, all resolutions were duly passed.

 

Accordingly, the following proposals become unconditional in all respects upon Admission of the Enlarged Ordinary Share Capital to trading on AIM, for which application has been made and is expected to occur at 8.00 a.m. on 4 July 2014:

 

· the acquisition by the Company of the entire issued share capital of Premaitha Health Limited, resulting in the admission of 95,454,545 Consideration Shares

 

· the Placing, resulting in the admission of 59,090,909 Placing Shares

 

· the Open Offer, resulting in the admission of 6,723,651 Open Offer Shares

 

· the Share Consolidation, resulting in the Company's Existing Ordinary Share Capital being consolidated into 26,894,601 New Ordinary Shares with a nominal value of 10 pence each

 

· New Board structure:

David Evans - Non-Executive Chairman

Dr Stephen Little - Chief Executive Officer

Peter Collins - Chief Commercial Officer

Mark Collingbourne - Finance Director

Dr Charles Roberts - Non-Executive Director

Adam Reynolds - Non-Executive Director

Nick Mustoe - Non-Executive Director

 

 

The Enlarged Ordinary Share Capital of the Company, comprising 188,163,709 New Ordinary Shares, will trade under the ISIN GB00BN31ZD89.

 

The change of the Company's name to Premaitha Health plc (AIM: NIPT), will become effective upon the registration of the Company's change of name at Companies House. A further announcement will be made in due course.

 

All of the defined terms in this announcement have the same meaning as in the Circular published by the Company and sent to shareholders on 13 June 2014. A copy can also be viewed on the Company's website.

 

 

Total Voting Rights

For the purposes of the Disclosure and Transparency Rules, the total number of voting rights in the Company with effect from 4 July 2014 will be 188,163,709. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

 

 

Enquiries:

 

ViaLogy PLC

Mark Collingbourne

 

 

Tel: +44 1620 810 183

 

Cairn Financial Advisers LLP

Nomad

Liam Murray

Avi Robinson

 

 

 

+44 20 7148 7900

 

Panmure Gordon (UK) Limited

Broker

Robert Naylor

Freddy Crossley

 

+44 20 7886 2500

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
REGLLFVIDEIVIIS
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.